Association between EHBP1 rs721048(A.G) polymorphism and prostate cancer susceptibility: A meta-analysis of 17 studies involving 150,678 subjects

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 1671-1680

  Ao, Xiang ^a   Liu, Ying ^a   Bai, Xiao Yan ^a   Qu, Xinjian ^a   Xu, Zhaowei ^a   Hu, Gaolei ^a   Chen, Min ^a   Wu, Huijian ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

EHBP1; Meta analysis; Prostate cancer; Rs721048

Indexed keywords

AFRICAN; ALLELE; ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; EHBP1 GENE; ETHNICITY; GENE; GENETIC ASSOCIATION; HUMAN; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84936940694     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S84034     Document Type: Article

References (46)

1. Siegel RD. American society of clinical oncology quality care symposium 2012: re-engineering your practice to deliver quality and value. J Oncol Pract. 2013;9(3):160-161.
2. Nelson AW, Tilley WD, Neal DE, Carroll JS. Estrogen receptor beta in prostate cancer: friend or foe? Endocr Relat Cancer. 2014;21(4):T219-T234.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
4. Hu B, Yang H, Yang H. Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 mug/L in patients with prostate cancer. Tumour Biol. 2014;35(9):8573-8580.
5. Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009;6(2):87-95.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
7. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388-1413.
8. Takata R, Akamatsu S, Kubo M, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010;42(9):751-754.
9. Akamatsu S, Takata R, Haiman CA, et al. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet. 2012;44(4):426-429,S421.
10. Haiman CA, Chen GK, Blot WJ, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011;43(6):570-573.
11. Xu J, Mo Z, Ye D, et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet. 2012;44(11):1231-1235.
12. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38(6):652-658.
13. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39(5):631-637.
14. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007;39(8):977-983.
15. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39(5):645-649.
16. Eeles RA, Kote-Jarai Z, Giles GG, et al; UK Genetic Prostate Cancer Study Collaborators, British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316-321.
17. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008;40(3):281-283.
18. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40(3):310-315.
19. Eeles RA, Kote-Jarai Z, Al Olama AA, et al; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, PRACTICAL Consortium. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009;41(10):1116-1121.
20. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet. 2009;41(10): 1122-1126.
21. Yeager M, Chatterjee N, Ciampa J, et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet. 2009;41(10):1055-1057.
22. Kote-Jarai Z, Olama AA, Giles GG, et al; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, The Australian Prostate Cancer BioResource, PRACTICAL Consortium. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011;43(8):785-791.
23. Guilherme A, Soriano NA, Furcinitti PS, Czech MP. Role of EHD1 and EHBP1 in perinuclear sorting and insulin-regulated GLUT4 recycling in 3T3-L1 adipocytes. J Biol Chem. 2004;279(38):40062-40075.
24. Guilherme A, Soriano NA, Bose S, et al. EHD2 and the novel EH domain binding protein EHBP1 couple endocytosis to the actin cytoskeleton. J Biol Chem. 2004;279(11):10593-10605.
25. Ghalali A, Wiklund F, Zheng H, Stenius U, Hogberg J. Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis. 2014;35(7):1547-1555.
26. Lindstrom S, Schumacher F, Siddiq A, et al. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers - results from BPC3. PLoS One. 2011;6(2):e17142.
27. Sun J, Kader AK, Hsu FC, et al. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate. 2011;71(4):421-430.
28. Tsilidis KK, Travis RC, Appleby PN, et al. Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Am J Epidemiol. 2012;175(9):926-935.
29. Waters KM, Le Marchand L, Kolonel LN, et al. Generalizability of associations from prostate cancer genome-wide association studies in multiple populations. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1285-1289.
30. Klein RJ, Hallden C, Gupta A, et al. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol. 2012;61(3):471-477.
31. Koutros S, Berndt SI, Hughes Barry K, et al. Genetic susceptibility loci, pesticide exposure and prostate cancer risk. PLoS One. 2013;8(4):e58195.
32. Nguyen Bentzon D, Nyegaard M, Børglum A, Ørntoft T, Borre M, Dalsgaard Sørensen K. Replication of prostate cancer risk variants in a Danish case-control association study. Open J Urol. 2012;2(2): 45-54.
33. Chang BL, Spangler E, Gallagher S, et al. Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev. 2011;20(1):23-32.
34. Haiman CA, Chen GK, Blot WJ, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet. 2011;7(5):e1001387.
35. Xu J, Kibel AS, Hu JJ, et al. Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2145-2149.
36. Wang Y, Ray AM, Johnson EK, Zuhlke KA, Cooney KA, Lange EM. Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study. Prostate. 2011;71(3):225-231.
37. Han Y, Signorello LB, Strom SS, et al; PRACTICAL Consortium, ELLIPSE GAME-ON Consortium. Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer. 2015;136(5):1210-1217.
38. Zheng SL, Hsing AW, Sun J, et al. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate. 2010;70(4):425-432.
39. Liu F, Hsing AW, Wang X, et al. Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men. Cancer Sci. 2011;102(10):1916-1920.
40. Na R, Liu F, Zhang P, et al. Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men. Prostate. 2013;73(15):1623-1635.
41. Zhang Q, Zheng M, Qi XL, Liu F, Mao ZJ, Zhang DH. Effect of NQO1 C609T polymorphism on prostate cancer risk: a meta-analysis. Onco Targets Ther. 2014;7:907-914.
42. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
43. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol. 2000;151(4):346-357.
44. Lou Y, Li R, Xiong L, et al. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2013;34(6):3967-3979.
45. Yang C, Li S, Wang M, et al. PTEN suppresses the oncogenic function of AIB1 through decreasing its protein stability via mechanism involving Fbw7 alpha. Mol Cancer. 2013;12:21.
46. Pan H, Niu W, He L, et al. Contributory role of five common polymorphisms of RAGE and APE1 genes in lung cancer among Han Chinese. PLoS One. 2013;8(7):e69018.